Advertisement
Document › Details
mySugr GmbH. (6/30/17). "Press Release: mySugr Joins the Roche family". San Diego, CA.
Organisation | mySugr GmbH | |
Today | Roche (Group) | |
Group | Roche (Group) | |
Organisation 2 | Roche Diabetes Care AG | |
Group | Roche (Group) | |
Product | mySugr app | |
Product 2 | glucose metering device | |
Index term | mySugr–Roche: investment, 201706 acquisition of remaining shares by Roche | |
Person | Westermann, Frank (mySugr 201706 CEO + Co-Founder) | |
Person 2 | Gmuender, Marcel (Roche 201706 Global Head Diabetes Care) | |
mySugr announced today that partner Roche is now the exclusive shareholder of mySugr GmbH. This partnership will accelerate mySugr’s international growth and enhance its focus on new diabetes technology. mySugr reported reaching more than one million users in May of 2017.
Founded by four passionate entrepreneurs, mySugr becomes the heart of Roche Diabetes Care’s new patient-centered digital health services. This alignment strengthens mySugr’s unmatched patient focus and unparalleled success. Both companies expect to be well-positioned for a rapidly changing diabetes marketplace.
“We started mySugr to solve our everyday problems and simplify diabetes therapy through smartphones,” said Frank Westermann, CEO & co-founder of mySugr, “The mySugr team has filled a gap for over a million loyal users so far, and with Roche’s diabetes expertise and global network, mySugr will become an indispensable companion for a hassle-free life.”
Roche Diabetes Care sees mySugr’s vision for the digitalization of diabetes care as a perfect fit for their evolving organization.
“It is very exciting to take our successful partnership with mySugr to the next level as it will constitute an integral part of our new, open digital health ecosystem centered around the needs of people with diabetes,” says Marcel Gmuender, Global Head of Roche Diabetes Care. “We are passionately working to redefine the way diabetes care is being provided so that people with diabetes are not only seamlessly connected to their caregivers but can experience relief from their daily routines while spending more time in their target range.”
Being a focal point for Roche Diabetes Care’s integrated digital health strategy, mySugr will remain a separate legal entity with an open platform for all diabetes devices and services used by people with diabetes.
About mySugr
Founded in 2012, mySugr specializes in all-around care for people with diabetes. Its apps and services beautifully combine diabetes coaching, therapy management, unlimited test-strips, automated data tracking, and seamless integration with a growing number of medical devices to ease the daily burden of living with diabetes. Early investors include business angel “Hansi” Hansmann, iSeed Ventures, and Roche Venture Fund. The company has offices in San Diego, California and Vienna, Austria with 47 employees across both locations. The mySugr App is available in 52 countries and 13 languages. For more information, please visit mySugr.com/press.
About Roche Diabetes Care
Roche Diabetes Care is a pioneer in the development of blood glucose monitoring systems and a global leader for diabetes management systems and services. For more than 40 years, the Accu-Chek brand has been dedicated to enabling people with diabetes to live life as normally and actively as possible as well as to empowering healthcare professionals to manage their patients’ condition in an optimal way. Today, the Accu-Chek portfolio offers people with diabetes and healthcare professionals innovative products and impactful solutions for convenient, efficient and effective diabetes management, spanning from blood glucose monitoring through information management to insulin delivery. The Accu-Chek brand encompasses blood glucose meters, insulin delivery systems, lancing devices, data management systems and education programs – contributing to an improved medical outcome.
Additional information:
Open letter from the founders: https://mysugr.com/hello-roche
Management team: https://mysugr.com/team/
mySugr Inc
111 C Street
Encinitas, CA 92024
mySugr.com
Press contact
Sara Westermann
Phone: +1 760 557 9825
Email: press@mysugr.com
Record changed: 2023-06-05 |
Advertisement
More documents for Roche (Group)
- [1] Freenome, Inc.. (2/15/24). "Press Release: Freenome Raises $254 Million in New Funding to Accelerate its Platform for Early Cancer Detection". South San Francisco, CA....
- [2] PathAI Inc.. (2/13/24). "Press Release: PathAI Announces Exclusive Collaboration with Roche Tissue Diagnostics to Advance AI-enabled Interpretation for Companion Diagnostics". Boston, MA....
- [3] Repare Therapeutics Inc.. (2/12/24). "Press Release: Repare Therapeutics to Regain Global Rights to Camonsertib". Cambridge, MA & Montréal....
- [4] Hookipa Pharma Inc.. (1/29/24). "Press Release: Hookipa Pharma Provides Update on Business Priorities and Oncology Partnership Programs". New York, NY & Vienna....
- [5] Repare Therapeutics Inc.. (1/25/24). "Press Release: Repare Therapeutics Announces Achievement of $40 Million Roche Clinical Milestone Payment". Cambridge, MA & Montréal....
- [6] Roche Deutschland Holding GmbH. (1/10/24). "Press Release: Prof. Hagen Pfundner wird zum 1. Mai 2024 Vorsitzender der Roche Deutschland Holding GmbH"....
- [7] Remix Therapeutics, Inc.. (1/3/24). "Press Release: Remix Therapeutics Enters Collaboration with Roche for the Discovery and Development of Small Molecule Therapeutics Modulating RNA Processing". Watertown, MA....
- [8] MediLink Therapeutics (Suzhou) Co., Ltd.. (1/2/24). "Press Release: MediLink Therapeutics Announces Worldwide Collaboration and License Agreement with Roche to Develop Next-generation Antibody Drug Conjugate in Oncology". Suzhou....
- [9] Roche. (12/29/23). "Press Release: Roche Enters into a Definitive Agreement to Acquire LumiraDx's Point of Care Technology Combining Multiple Diagnostic Modalities on a Single Platform". Basel....
- [10] Roche. (12/4/23). "Press Release: Roche Enters into a Definitive Merger Agreement to Acquire Carmot Therapeutics, including Three Clinical Stage Assets with Best-in-class Potential in Obesity and Diabetes". Basel....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top